Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non‐small cell lung cancer: Updated follow‐up results from two phase II trials-Reference-Cited by-同舟云学术

Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non‐small cell lung cancer: Updated follow‐up results from two phase II trials

Published:2020-04 Issue:4 Volume:11 Page:898-906
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Honglian Ma¹²,Zhouguang Hui³^ORCID,Fang PENG⁴,Lujun Zhao⁵,Dongming Li⁶,Yujin Xu²,Yong Bao⁴,Liming Xu⁵,Yirui Zhai³,Xiao Hu²,Jin Wang²,Yue Kong²,Lvhua Wang³,Ming Chen²

Affiliation:

1. Department of Radiation OncologyThe Second Affiliated Hospital of Soochow University Suzhou China

2. Department of Radiation OncologyCancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital Hangzhou China

3. Department of Radiation OncologyChinese Academy of Medical Sciences and Peking Union Medical College Beijing China

4. Department of Radiation OncologySun Yat‐sen University First Affiliated Hospital Guangzhou China

5. Department of Radiation OncologyTianjin Medical University Cancer Institute and Hospital Tianjin China

6. Department of Radiation OncologyBeijing Cancer Hospital Beijing China

Funder

Co-cultivation project of National Health Commission of the People's Republic of China and Zhejiang province

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13333

Reference37 articles.

1. Concurrent Cisplatin, Etoposide, and Chest Radiotherapy in Pathologic Stage IIIB Non–Small-Cell Lung Cancer: A Southwest Oncology Group Phase II Study, SWOG 9019

2. Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

3. Results of randomized, multicenter, double‐blind phase III trial of rh‐endostatin (YH‐16) in treatment of advanced non‐small cell lung cancer patients;Jinwan W;Zhongguo Fei Ai Za Zhi,2005

4. Randomized phase II trial on escalated doses of Rh‐endostatin (YH‐16) for advanced non‐small cell lung cancer;Yang L;Zhonghua Zhong Liu Za Zhi,2006

5. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: A meta‐analysis;Ge W;Asian Pac J Cancer Prev,2011

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances progress of targeted drugs combined with radiotherapy for advanced non-small cell lung cancer: a review;Frontiers in Oncology;2023-12-05

2. A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC;BMC Pulmonary Medicine;2023-11-11

3. Recombinant Endostatin as a Potential Radiosensitizer in the Treatment of Non-Small Cell Lung Cancer;Pharmaceuticals;2023-01-31

4. Ameliorating Fibrosis in Murine and Human Tissues with END55, an Endostatin-Derived Fusion Protein Made in Plants;Biomedicines;2022-11-09

5. Tumor angiogenesis at baseline identified by 18F-Alfatide II PET/CT may predict survival among patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy;Journal of Translational Medicine;2022-02-02